US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

PPD, Inc.

47.28

+0.0000

Volume:- -

Turnover:- -

Market Cap:16.61B

PE:47.03

High:47.28

Open:47.28

Low:47.28

Close:47.28

Loading ...

Overview Company News Filings

Sage Therapeutics, Inc. (SAGE): Among the Best Psychedelic Stocks to Buy in 2025

GH Research Reports Full Year 2024 Financial Results and Provides Business Updates

Lipocine Receives Updated Regulatory Guidance on LPCN 1154

SAGE Rejects Biogen's Offer to Buy Remaining Stake, Stock Up

FDA To Review Under the Skin Weekly Autoinjector For Biogen/Eisai's Alzheimer's Drug Leqembi

Biogen Offers to Buy Remaining Stake in Sage Therapeutics

Why Is Depression-Focused Sage Therapeutics Stock Surging Higher On Monday?

GH Research Announces Primary Endpoint Met in Two Phase 2a POC Trials with GH001 and Completion of All FDA Requests to Address IND Hold with No Findings of Respiratory Toxicity in Non-Rodents

Press Release: Centessa Pharmaceuticals Announces Appointment of Stephen Kanes, MD PhD, as Chief Medical Officer

Biogen Stock Declines 21.4% in 3 Months: How to Play the Stock

GH Research Reports Third Quarter 2024 Financial Results and Provides Business Updates

Press Release: Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2024

Sobi to present new data across its immunology portfolio at the ACR Convergence 2024

Sage Therapeutics to Reduce Workforce by 33%, Stock Down

Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results

It’s an Impressive Result – Ray Dalio About Duoduo Grocery’s Contribution to PPD Holding Inc (PDD)’s Annual Profits

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/PPD/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PPD"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PPD\",,,,,undefined,":{"symbol":"PPD","market":"US","secType":"STK","nameCN":"PPD, Inc.","latestPrice":47.28,"timestamp":1741381200000,"preClose":47.28,"halted":3,"volume":0,"delay":0,"changeRate":0,"change":0,"floatShares":117802105,"shares":351394547,"eps":1.005366,"lyrEps":0.352171,"pbRate":-39.14,"amount":0,"amplitude":0,"volumeRatio":1.2485646409899478,"dividePrice":0,"prevYearClose":47.28,"fiveDayClose":47.28,"twentyDayClose":47.28,"impliedVol":0.1492,"impliedVolPercentile":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PPD\",,,,,undefined,":{"symbol":"PPD","floatShares":117802105,"roa":"6.39%","roe":"-27.30%","lyrEps":0.352171,"volumeRatio":1.2485646409899478,"shares":351394547,"dividePrice":0,"high":47.28,"amplitude":0,"preClose":47.28,"low":47.28,"week52Low":47.28,"pbRate":"-39.14","week52High":47.28,"institutionHeld":0,"latestPrice":47.28,"eps":1.005366,"divideRate":0,"volume":0,"delay":0,"ttmEps":1.005366,"open":47.28,"prevYearClose":47.28,"prevWeekClose":47.28,"prevMonthClose":47.28,"prevQuarterClose":47.28,"fiveDayClose":47.28,"twentyDayClose":47.28,"sixtyDayClose":47.28},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PPD\",params:#limit:5,,,undefined,":[{"date":"2021-10-28","symbol":"PPD","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2021/09","expectedEps":0.35,"defaultRemindTime":1635451200000,"name":null,"time":"Post Market","dateTimestamp":1635393600000,"actualEps":null},{"market":"US","date":"2021-07-28","symbol":"PPD","fiscalQuarterEnding":"2021/06","expectedEps":0.34,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1627444800000,"reportTimeType":"post","actualEps":0.36},{"market":"US","date":"2021-04-27","symbol":"PPD","fiscalQuarterEnding":"2021/03","expectedEps":0.31,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1619496000000,"reportTimeType":"post","actualEps":0.33},{"market":"US","date":"2021-02-23","symbol":"PPD","fiscalQuarterEnding":"2020/12","expectedEps":0.34,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1614056400000,"reportTimeType":"post","actualEps":0.38},{"market":"US","date":"2020-10-27","symbol":"PPD","fiscalQuarterEnding":"2020/09","expectedEps":0.15,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1603771200000,"reportTimeType":"post","actualEps":0.15}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PPD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PPD\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PPD\",params:#withValueCompare:true,withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PPD","date":"2021-12-09","current":45.63553,"percent":0.035165,"low":45.461791,"twenty":76.447997,"median":144.910788,"eighty":183.913548,"high":257.573166,"avg":133.670985,"sd":56.331588,"marketCap":16613934182},"quantilePoints":[{"date":"2020-03-13","current":167.653326,"twenty":206.110064,"median":223.956224,"eighty":243.356561,"marketCap":8017349706},{"date":"2020-03-20","current":105.840274,"twenty":175.700686,"median":218.470942,"eighty":243.139039,"marketCap":5061387727},{"date":"2020-03-27","current":123.917676,"twenty":132.125399,"median":211.322611,"eighty":242.590511,"marketCap":5925867174},{"date":"2020-04-03","current":122.386928,"twenty":125.375531,"median":206.110064,"eighty":239.601253,"marketCap":5852665285},{"date":"2020-04-09","current":169.111181,"twenty":128.014248,"median":198.632745,"eighty":235.812711,"marketCap":8087065790},{"date":"2020-04-17","current":162.18637,"twenty":129.90946,"median":178.441453,"eighty":233.743667,"marketCap":7755914389},{"date":"2020-04-24","current":164.081581,"twenty":130.390552,"median":168.382254,"eighty":228.360652,"marketCap":7846545299},{"date":"2020-05-01","current":165.612329,"twenty":131.7172,"median":168.528039,"eighty":225.429414,"marketCap":7919747187},{"date":"2020-05-08","current":203.176752,"twenty":135.522202,"median":171.297964,"eighty":224.050258,"marketCap":9565155140},{"date":"2020-05-15","current":203.69506,"twenty":139.268889,"median":174.286566,"eighty":223.611435,"marketCap":9589556046},{"date":"2020-05-22","current":201.918004,"twenty":144.779581,"median":178.078817,"eighty":221.981523,"marketCap":9505895797},{"date":"2020-05-29","current":201.695872,"twenty":145.129466,"median":193.847207,"eighty":218.470942,"marketCap":9495438266},{"date":"2020-06-05","current":201.769916,"twenty":151.689814,"median":195.784018,"eighty":215.493218,"marketCap":9498924109},{"date":"2020-06-12","current":189.922875,"twenty":157.812805,"median":195.425464,"eighty":211.691813,"marketCap":8941189116},{"date":"2020-06-19","current":199.178376,"twenty":160.364051,"median":197.364298,"eighty":211.461869,"marketCap":9376919579},{"date":"2020-06-26","current":194.735736,"twenty":160.509837,"median":197.919628,"eighty":211.183354,"marketCap":9167768957},{"date":"2020-07-02","current":199.030288,"twenty":160.976351,"median":197.919628,"eighty":211.11624,"marketCap":9369947892},{"date":"2020-07-10","current":215.394013,"twenty":161.967692,"median":198.51198,"eighty":211.239057,"marketCap":10140319352},{"date":"2020-07-17","current":223.020546,"twenty":163.702539,"median":198.632745,"eighty":211.721431,"marketCap":10499361254},{"date":"2020-07-24","current":220.280918,"twenty":164.19821,"median":199.104332,"eighty":215.695509,"marketCap":10370385037},{"date":"2020-07-31","current":217.467245,"twenty":164.518938,"median":199.474552,"eighty":216.697187,"marketCap":10237922976},{"date":"2020-08-07","current":142.465689,"twenty":163.702539,"median":199.43753,"eighty":217.667984,"marketCap":11147940180},{"date":"2020-08-14","current":138.010852,"twenty":159.853802,"median":199.030288,"eighty":216.697187,"marketCap":10799349180},{"date":"2020-08-21","current":141.88656,"twenty":144.353742,"median":198.609385,"eighty":216.326967,"marketCap":11102623350},{"date":"2020-08-28","current":151.419912,"twenty":145.041995,"median":198.437936,"eighty":215.651083,"marketCap":11848608090},{"date":"2020-09-04","current":143.757592,"twenty":145.041995,"median":197.512386,"eighty":215.413854,"marketCap":11249031570},{"date":"2020-09-11","current":149.905267,"twenty":145.883354,"median":195.957462,"eighty":214.994175,"marketCap":11730087150},{"date":"2020-09-18","current":150.796235,"twenty":145.883354,"median":195.425464,"eighty":214.683191,"marketCap":11799805350},{"date":"2020-09-25","current":150.306202,"twenty":146.626507,"median":194.735736,"eighty":213.631766,"marketCap":11761460340},{"date":"2020-10-02","current":158.770393,"twenty":146.920526,"median":193.847207,"eighty":212.284165,"marketCap":12423783240},{"date":"2020-10-09","current":164.517133,"twenty":147.009623,"median":187.255354,"eighty":211.751048,"marketCap":12873465630},{"date":"2020-10-16","current":162.601553,"twenty":147.624391,"median":174.578137,"eighty":211.553847,"marketCap":12723571500},{"date":"2020-10-23","current":158.057619,"twenty":148.381713,"median":174.104334,"eighty":211.29476,"marketCap":12368008680},{"date":"2020-10-30","current":163.434526,"twenty":149.121215,"median":169.111181,"eighty":211.133018,"marketCap":11496638283},{"date":"2020-11-06","current":178.14761,"twenty":149.620158,"median":170.204572,"eighty":210.477491,"marketCap":12531615452},{"date":"2020-11-13","current":172.033727,"twenty":149.83399,"median":169.150758,"eighty":209.109098,"marketCap":12101540479},{"date":"2020-11-20","current":167.758979,"twenty":150.012183,"median":169.130969,"eighty":208.316353,"marketCap":11800837653},{"date":"2020-11-27","current":174.32022,"twenty":150.10128,"median":168.892503,"eighty":208.15251,"marketCap":12262381526},{"date":"2020-12-04","current":173.22668,"twenty":150.199286,"median":170.34371,"eighty":207.974804,"marketCap":12185457547},{"date":"2020-12-11","current":171.089306,"twenty":150.306202,"median":171.0396,"eighty":207.78229,"marketCap":12035106134},{"date":"2020-12-18","current":173.723743,"twenty":150.413118,"median":171.089306,"eighty":207.426879,"marketCap":12220422992},{"date":"2020-12-24","current":173.22668,"twenty":150.582403,"median":172.033727,"eighty":206.843646,"marketCap":12185457547},{"date":"2020-12-31","current":167.162503,"twenty":150.618041,"median":171.297964,"eighty":206.110064,"marketCap":11758879119},{"date":"2021-01-08","current":180.831753,"twenty":150.65368,"median":171.665845,"eighty":206.110064,"marketCap":12720428854},{"date":"2021-01-15","current":178.644673,"twenty":150.92097,"median":172.630203,"eighty":206.056518,"marketCap":12566580897},{"date":"2021-01-22","current":174.270513,"twenty":151.419912,"median":173.22668,"eighty":205.842336,"marketCap":12258884981},{"date":"2021-01-29","current":160.800088,"twenty":151.689814,"median":173.176973,"eighty":204.80572,"marketCap":11311321425},{"date":"2021-02-05","current":176.209061,"twenty":151.738319,"median":173.22668,"eighty":204.716867,"marketCap":12395250217},{"date":"2021-02-12","current":185.007088,"twenty":151.98132,"median":173.350945,"eighty":204.228177,"marketCap":13014138591},{"date":"2021-02-19","current":181.627055,"twenty":152.177234,"median":173.524918,"eighty":203.69506,"marketCap":12776373566},{"date":"2021-02-26","current":80.259419,"twenty":151.932341,"median":173.574624,"eighty":203.546972,"marketCap":12335150360},{"date":"2021-03-05","current":76.447997,"twenty":150.618041,"median":173.350945,"eighty":203.176752,"marketCap":11749369125},{"date":"2021-03-12","current":83.291552,"twenty":150.128009,"median":173.22668,"eighty":203.102708,"marketCap":12801161908},{"date":"2021-03-19","current":84.5684,"twenty":149.673616,"median":172.729616,"eighty":202.806532,"marketCap":12997402003},{"date":"2021-03-26","current":84.04398,"twenty":147.009623,"median":172.133139,"eighty":202.495547,"marketCap":12916803393},{"date":"2021-04-01","current":86.278465,"twenty":145.883354,"median":171.193635,"eighty":202.258606,"marketCap":13260223559},{"date":"2021-04-09","current":86.278465,"twenty":143.401205,"median":170.989893,"eighty":202.006857,"marketCap":13260223559},{"date":"2021-04-16","current":104.427952,"twenty":142.519147,"median":169.772087,"eighty":201.829151,"marketCap":16049636337},{"date":"2021-04-23","current":105.51948,"twenty":141.565812,"median":169.150758,"eighty":201.72549,"marketCap":16217394416},{"date":"2021-04-30","current":75.253588,"twenty":138.919639,"median":168.688612,"eighty":201.296034,"marketCap":16210375419},{"date":"2021-05-07","current":75.194137,"twenty":130.652966,"median":168.382254,"eighty":200.451933,"marketCap":16197568982},{"date":"2021-05-14","current":75.096376,"twenty":123.305377,"median":168.082071,"eighty":199.844772,"marketCap":16176510387},{"date":"2021-05-21","current":75.16155,"twenty":112.050736,"median":167.653326,"eighty":199.563405,"marketCap":16190549450},{"date":"2021-05-28","current":75.224773,"twenty":105.533181,"median":167.311622,"eighty":199.430126,"marketCap":16204168444},{"date":"2021-06-04","current":75.43672,"twenty":105.419007,"median":166.934112,"eighty":199.311655,"marketCap":16249823882},{"date":"2021-06-11","current":75.84431,"twenty":102.108165,"median":165.820431,"eighty":199.119141,"marketCap":16337622801},{"date":"2021-06-18","current":75.469327,"twenty":87.73316,"median":164.805363,"eighty":198.911818,"marketCap":16256847795},{"date":"2021-06-25","current":75.338899,"twenty":87.327305,"median":164.684214,"eighty":198.713839,"marketCap":16228752141},{"date":"2021-07-02","current":75.126952,"twenty":86.360548,"median":164.294391,"eighty":198.623401,"marketCap":16183096704},{"date":"2021-07-09","current":74.670451,"twenty":85.982054,"median":164.081581,"eighty":198.586024,"marketCap":16084761915},{"date":"2021-07-16","current":74.80088,"twenty":85.275227,"median":163.75981,"eighty":198.586024,"marketCap":16112857569},{"date":"2021-07-23","current":74.996523,"twenty":83.49676,"median":163.447972,"eighty":198.437936,"marketCap":16155001050},{"date":"2021-07-30","current":79.332562,"twenty":81.302924,"median":163.202956,"eighty":198.363892,"marketCap":16223588160},{"date":"2021-08-06","current":79.024087,"twenty":79.912546,"median":162.539811,"eighty":197.919628,"marketCap":16160504904},{"date":"2021-08-13","current":79.195879,"twenty":79.402029,"median":161.06767,"eighty":197.105144,"marketCap":16195636436},{"date":"2021-08-20","current":79.075625,"twenty":79.230237,"median":160.596876,"eighty":196.142572,"marketCap":16171044363},{"date":"2021-08-27","current":79.625358,"twenty":79.240544,"median":160.531082,"eighty":195.92044,"marketCap":16283465267},{"date":"2021-09-03","current":80.243807,"twenty":79.293488,"median":160.195941,"eighty":195.639073,"marketCap":16409938784},{"date":"2021-09-10","current":80.089195,"twenty":79.327546,"median":158.503103,"eighty":195.500318,"marketCap":16378320404},{"date":"2021-09-17","current":80.226628,"twenty":79.346605,"median":157.864962,"eighty":195.416131,"marketCap":16406425630},{"date":"2021-09-24","current":80.449957,"twenty":79.381414,"median":156.587523,"eighty":195.135574,"marketCap":16452096622},{"date":"2021-10-01","current":80.38124,"twenty":79.402029,"median":153.135024,"eighty":194.735736,"marketCap":16438044009},{"date":"2021-10-08","current":80.570211,"twenty":79.422644,"median":152.266331,"eighty":194.528412,"marketCap":16476688695},{"date":"2021-10-15","current":80.638927,"twenty":79.460438,"median":151.811078,"eighty":194.069339,"marketCap":16490741308},{"date":"2021-10-22","current":80.810719,"twenty":79.505103,"median":150.796235,"eighty":192.277474,"marketCap":16525872840},{"date":"2021-10-29","current":81.085638,"twenty":79.563513,"median":150.439848,"eighty":189.586929,"marketCap":16582094100},{"date":"2021-11-05","current":45.645182,"twenty":79.402029,"median":150.128009,"eighty":189.00348,"marketCap":16617448127},{"date":"2021-11-12","current":45.606574,"twenty":79.27813,"median":149.81617,"eighty":188.4392,"marketCap":16603392345},{"date":"2021-11-19","current":45.606574,"twenty":79.209029,"median":148.613364,"eighty":187.358628,"marketCap":16603392345},{"date":"2021-11-26","current":45.703095,"twenty":79.034395,"median":147.009623,"eighty":186.392604,"marketCap":16638531800},{"date":"2021-12-03","current":45.54866,"twenty":78.97255,"median":146.586413,"eighty":184.78838,"marketCap":16582308672},{"date":"2021-12-09","current":45.63553,"twenty":76.447997,"median":144.910788,"eighty":183.913548,"marketCap":16613934182}],"customCompares":[]},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PPD\",pageSize:16,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2516569505","title":"Sage Therapeutics, Inc. (SAGE): Among the Best Psychedelic Stocks to Buy in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2516569505","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516569505?lang=en_us&edition=fundamental","pubTime":"2025-03-02 04:19","pubTimestamp":1740860399,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 12 Best Psychedelic Stocks to Buy in 2025.In this article, we are going to take a look at where Sage Therapeutics, Inc.  stands against the other psychedelic stocks.The Therapeutic Potential and Investment Boom in Psychedelic Medicine. Psilocybin  is the most widely used psychedelic drug in the United States, with an estimated 8 million American adults using it in 2023, according to a survey conducted by RAND Corporation. Around 12% of respondents reported lifetime use, and 3.1% used it in the past year. LSD use has also risen significantly, particularly among individuals aged 18-25, with usage increasing from 0.9% in 2002 to 4% in 2019. The LSD market is projected to grow from $145.9 million in 2024 to $265.7 million by 2034. MDMA, although not providing specific usage data, remains popular, especially in research for PTSD treatment. Ketamine has gained attention for its depression","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sage-therapeutics-inc-sage-among-201959349.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PSQ","PPD","SAGE","MNQmain","QLD","TSYW.SI","USJW.SI","TQQQ","NVIW.SI","NQmain","SQQQ","BK4561","BK4139","BK4121","BK4530","USAW.SI","QID",".IXIC"],"gpt_icon":1},{"id":"2514780569","title":"GH Research Reports Full Year 2024 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2514780569","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514780569?lang=en_us&edition=fundamental","pubTime":"2025-02-27 20:00","pubTimestamp":1740657600,"startTime":"0","endTime":"0","summary":"Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for completion of last patient visit in the open-label extension in Q1 2025. Phase 1 clinical trial to evaluate proprietary aerosol delivery device in healthy volunteers is ongoing in the UK. Full response to the IND hold on track for submission in mid-2025. Cash, cash equivalents, other financial assets and marketable securities of $182.6 million as of December 31, 2024. Net cash proceeds of an additional $139.8 million from public offering received in February 2025. DUBLIN, Feb. 27, 2025  -- GH Research PLC , a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today reported financial results for the year ended December 31, 2024, and provided updates on its business.As previously announced, our Investigational New Drug Application  for GH001 administered using our proprietary aerosol delivery device","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gh-research-reports-full-2024-120000403.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GH","BK4551","BK4585","BK4535","BK4561","BK4539","GHRS","PPD","BK4196","BK4121","BK4007","BK4588","BK4530"],"gpt_icon":0},{"id":"2509273678","title":"Lipocine Receives Updated Regulatory Guidance on LPCN 1154","url":"https://stock-news.laohu8.com/highlight/detail?id=2509273678","media":"PR Newswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509273678?lang=en_us&edition=fundamental","pubTime":"2025-02-06 21:00","pubTimestamp":1738846800,"startTime":"0","endTime":"0","summary":"SALT LAKE CITY, Feb. 6, 2025 /PRNewswire/ -- Lipocine Inc. , a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced receipt of revised regulatory guidance for LPCN 1154 which the Company is developing for postpartum depression  treatment. As previously disclosed, the Company was scheduled to meet with the U.S. Food and Drug Administration  in Q1 2025 to discuss the NDA submission package of LPCN 1154. Following the meeting, the Company was advised that the Division believes, in addition to the previously completed PK bridge data, an efficacy and safety study of oral LPCN 1154 in the target populationwillbe required for 505 NDA submission.Lipocine remains committed to advancing a rapid relief treatment for postpartum depression. Based on the guidance received and observed comparable exposure of LPCN 1154 and the reference drug in the completed PK bridge study, Lipocine is planning next steps tow","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/lipocine-receives-updated-regulatory-guidance-130000094.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lipocine-receives-updated-regulatory-guidance-130000094.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4121","LPCN","BK4530","BK4007","BK4561","PPD"],"gpt_icon":0},{"id":"2507542821","title":"SAGE Rejects Biogen's Offer to Buy Remaining Stake, Stock Up","url":"https://stock-news.laohu8.com/highlight/detail?id=2507542821","media":"Zacks","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507542821?lang=en_us&edition=fundamental","pubTime":"2025-01-29 00:54","pubTimestamp":1738083240,"startTime":"0","endTime":"0","summary":"Sage Therapeutics SAGE announced that its board of directors has rejected the unsolicited, non-binding proposal offer from drug giant Biogen BIIB to acquire the remaining shares of SAGE.Per Sage Therapeutics, the BIIB offer significantly undervalues the company and is not in the best interest of shareholders.SAGE’s board of directors has now started exploring strategic alternatives and evaluating other options to maximize its shareholders’ value.Shares of SAGE were up 4.8% on Jan. 27 following the news announcement.In the past year, the stock has plunged 72% compared with the industry’s decline of 12.4%.Earlier this month, Biogen made an acquisition offer to buy the remaining shares of SAGE that it does not already own for $7.22 per share. The offer price represented a premium of 30% on Sage Therapeutics’ closing price of $5.55 on Jan. 10.Biogen currently owns a 10.2% stake in SAGE, per a SEC filing by the company.Some better-ranked stocks in the biotech sector are Harmony Biosciences ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sage-rejects-biogens-offer-buy-165400180.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B19Z9Z06.USD","BK4139","BK4532","BK4007","BK4585","BK4581","IE00B19Z9P08.USD","LU0234570918.USD","BK4533","BK4121","LU0109394709.USD","IE00B894F039.SGD","BK4590","ET","SAGE","BK4561","BIIB","LU0889565916.HKD","CSTL","MCI","HRMY","PPD","BK4144","BK4530","BK4196","BK4588","LU0320765992.SGD"],"gpt_icon":0},{"id":"2503650859","title":"FDA To Review Under the Skin Weekly Autoinjector For Biogen/Eisai's Alzheimer's Drug Leqembi","url":"https://stock-news.laohu8.com/highlight/detail?id=2503650859","media":"Benzinga","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503650859?lang=en_us&edition=fundamental","pubTime":"2025-01-14 22:04","pubTimestamp":1736863460,"startTime":"0","endTime":"0","summary":"On Monday, the FDA accepted Eisai Co., Ltd.  and Biogen Inc’s  Biologics License Application  for lecanemab-irmb  subcutaneous autoinjector  for weekly maintenance dosing.Leqembi is indicated for Alzheimer’s disease in patients with Mild Cognitive Impairment or mild dementia stage of the disease.A Prescription Drug User Fee Act  action date is August 31, 2025.The BLA is based on data from the Clarity AD  open-label extension  and modeling of observed data.Also Read: Biogen Downgraded On Pipeline Setbacks And Leqembi Sales Slowdown. If the FDA approves Leqembi subcutaneous maintenance dosing, Leqembi will be the only treatment for AD that can be administered subcutaneously at home using an autoinjector.The injection process is expected to take, on average, 15 seconds. As part of the SC-AI 360 mg weekly maintenance regimen, patients who have completed the biweekly intravenous  initiation phase, the exact period under discussion with the FDA, would receive weekly doses expected to maintai","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fda-review-under-skin-weekly-140420876.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AAIC","BK4110","IE00B19Z9Z06.USD","BK4530","PPD","BK4561","IE00B894F039.SGD","LU0234570918.USD","IE00B19Z9P08.USD","LU0889565916.HKD","BK4588","LU0109394709.USD","BK4585","BK4532","BK4139","BK4121","BK4533","LU0320765992.SGD","BIIB"],"gpt_icon":0},{"id":"2503555448","title":"Biogen Offers to Buy Remaining Stake in Sage Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2503555448","media":"Zacks","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503555448?lang=en_us&edition=fundamental","pubTime":"2025-01-14 04:00","pubTimestamp":1736798400,"startTime":"0","endTime":"0","summary":"Sage Therapeutics  said Biogen  has made an unsolicited offer to acquire the rest of SAGE shares.Biogen currently owns a 10.2% stake in Sage Therapeutics; SAGE board members will review the offer.Sage Therapeutics SAGE announced that its partner Biogen BIIB has made an unsolicited, non-binding proposal offer to acquire the SAGE shares that it does not already own for $7.22per share. The offer price represents a premium of 30% on Sage Therapeutics’ closing price of $5.55 on Friday.At present, Biogen owns a 10.2% stake in SAGE, per a SEC filing by the company. Sage Therapeutics’ board will review and evaluate the offer and will come to a final decision.SAGE’s stock was up 46% in after-hours trading on Friday in response to the news while Biogen was down slightly.Biogen’s shares have declined 40%, while Sage Therapeutics’ stock has been down 79.1% in the past year, compared with a decrease of 15.9% for the industry.In September, Biogen terminated its rights under the collaboration and lic","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biogen-offers-buy-remaining-stake-200000531.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0889565916.HKD","BK4561","BK4139","BK4533","ABVC","LU0109394709.USD","PBYI","LU0320765992.SGD","BIIB","IE00B19Z9Z06.USD","CSTL","BK4581","BK4196","BK4530","BK4144","PPD","ET","MCI","IE00B19Z9P08.USD","SAGE","LU0234570918.USD","IE00B894F039.SGD","BK4590","BK4585","BK4588","BK4121","BK4532"],"gpt_icon":0},{"id":"2503258330","title":"Why Is Depression-Focused Sage Therapeutics Stock Surging Higher On Monday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2503258330","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503258330?lang=en_us&edition=fundamental","pubTime":"2025-01-13 22:38","pubTimestamp":1736779121,"startTime":"0","endTime":"0","summary":"On Friday, Sage Therapeutics Inc.  confirmed thatBiogen Inc. submitted an unsolicited, nonbinding proposal to acquire all of the outstanding shares ofSage Therapeuticsnot already owned by Biogen for$7.22per share.The Sage Board of Directors will carefully review and evaluate Biogen’s proposal.Also Read: After Failed Alzheimer’s Study, Sage Therapeutics’ Dalzanemdor Flunks Another Study In Patients With Inherited Brain Disorder. In November 2020, Biogen andSage Therapeutics executed a global collaboration and license agreement to jointly develop and commercialize zuranolone  for major depressive disorder , postpartum depression  and other psychiatric disorders and SAGE-324 for essential tremor and other neurological disorders.Over the last five years, Sage stock has slumped 90%.In October last year, Sage Therapeutics announced a strategic reorganization of its business operations to support the ongoing launch of Zurzuvae in postpartum depression.The company said the reorganization was i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-depression-focused-sage-therapeutics-143841762.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B894F039.SGD","SAGE","BK4533","BK4139","LU0109394709.USD","BK4530","BK4121","BK4585","BIIB","BK4532","BK4561","IE00B19Z9P08.USD","LU0234570918.USD","IE00B19Z9Z06.USD","LU0889565916.HKD","PPD","BK4588","LU0320765992.SGD"],"gpt_icon":0},{"id":"2502528748","title":"GH Research Announces Primary Endpoint Met in Two Phase 2a POC Trials with GH001 and Completion of All FDA Requests to Address IND Hold with No Findings of Respiratory Toxicity in Non-Rodents","url":"https://stock-news.laohu8.com/highlight/detail?id=2502528748","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502528748?lang=en_us&edition=fundamental","pubTime":"2025-01-10 20:00","pubTimestamp":1736510400,"startTime":"0","endTime":"0","summary":"Primary endpoint met in phase 2a POC trial in postpartum depression with a MADRS reduction from baseline of –35.4 points(p<0.0001, n=10) and 100% of patients in remission at Day 8Primary endpoint met ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/10/3007557/0/en/GH-Research-Announces-Primary-Endpoint-Met-in-Two-Phase-2a-POC-Trials-with-GH001-and-Completion-of-All-FDA-Requests-to-Address-IND-Hold-with-No-Findings-of-Respiratory-Toxicity-in-.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","IDR","BK4585","GH","BK4196","PPD","BK4561","BK4588","BK4168","BK4121","BK4530","BK4551"],"gpt_icon":0},{"id":"2501723047","title":"Press Release: Centessa Pharmaceuticals Announces Appointment of Stephen Kanes, MD PhD, as Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2501723047","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501723047?lang=en_us&edition=fundamental","pubTime":"2025-01-08 20:05","pubTimestamp":1736337900,"startTime":"0","endTime":"0","summary":"BOSTON and LONDON, Jan. 08, 2025  -- Centessa Pharmaceuticals plc , a clinical stage pharmaceutical company with a mission to discover, develop and ultimately deliver medicines that are transformational for patients, today announced the appointment of Stephen Kanes MD PhD, as Chief Medical Officer . Dr. Kanes is a neuropsychiatrist, with a career in neuroscience, clinical psychiatry, and neuroscience drug development spanning more than 30 years.\"Orexin agonists are one of the most exciting emerging areas of therapeutic science, and Centessa's potential best-in-class OX2R agonists represent an extraordinary opportunity to address unmet patient needs across multiple therapeutic areas,\" said Stephen Kanes, MD PhD, Chief Medical Officer. \"With Phase 2a clinical studies of ORX750 now underway, it's an exciting time to be joining Centessa. I look forward to working with the team and contributing to the success of the Company's growing OX2R agonist franchise.\"","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4571","BK4539","BK4530","IE00BYTNYN87.SGD","BK4022","BK4139","BK4552","MD","BK4085","01698","BK4531","IE00B12V2V27.USD","LU1023057109.AUD","BK4565","R","BK4535","SG9999011746.SGD","LU2039709279.SGD","BK4509","IE00BYQNZ168.SGD","PPD","BK4510","BK4561","BK4232","BK4563","BK4121","BK4196","CMO","TME","LU0359201612.USD","IH","CNTA","BK4108","BK4526","BK4548","LU0359202008.SGD"],"gpt_icon":0},{"id":"2490960048","title":"Biogen Stock Declines 21.4% in 3 Months: How to Play the Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2490960048","media":"Zacks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490960048?lang=en_us&edition=fundamental","pubTime":"2024-12-10 21:32","pubTimestamp":1733837520,"startTime":"0","endTime":"0","summary":"Biogen BIIB stock has declined 21.4% in the past three months against a decrease of 12.3% for the industry. The stock has also underperformed the sector and the S&P 500 index, as seen in the chart below.BIIB Stock Underperforms Industry, Sector & S&P 500. Sales of MS drugs and Spinraza are declining due to competitive pressure. Tecfidera revenues are declining as multiple generic versions have been launched in North America, Brazil and certain European countries. Regulatory applications seeking approval for a biosimilar referencing Tysabri have been approved in the United States and Europe. A Tysabri biosimilar is now available in some European countries, which has begun to hurt growth. Additional launches in the United States and other countries are expected in the near term. Spinraza sales declined almost 13.3% in the first nine months of 2024 due to increased competitive pressure and a decrease in demand. Sales of MS drugs and Spinraza are not expected to show any significant improv","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/vtsVt8PEmb10KQ4cnwEJfQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/96776645e0ac7ab203b7d5e3b37251a6","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/vtsVt8PEmb10KQ4cnwEJfQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/96776645e0ac7ab203b7d5e3b37251a6"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biogen-stock-declines-21-4-133200941.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LLY","LU2028103732.USD","IE00B4R5TH58.HKD","LU2491050071.SGD","LU0820561909.HKD","LU2602419157.SGD","IE0002141913.USD","LU2357305700.SGD","LU2324357040.USD","IE00BZ1G4Q59.USD","LU0058720904.USD","LU2089984988.USD","LU0098860793.USD","SGXZ81514606.USD","LU0106831901.USD","IE0009355771.USD","SAGE","LU2023251221.USD","LU0320765059.SGD","LU0256863902.USD","LU1064131342.USD","LU1868837300.USD","GB00BDT5M118.USD","LU0320765992.SGD","LU1868836914.USD","SGXZ51526630.SGD","BIIB","LU0466842654.USD","LU0385154629.USD","SGXZ99366536.SGD","LU0314104364.USD","LU1023059063.AUD","LU0096364046.USD","LU0882574139.USD","LU2237443465.HKD","LU2361044949.HKD","IE00BK4W5L77.USD","LU2023250504.SGD","LU2360106947.USD","LU1551013342.USD","LU1623119135.USD","PPD","SG9999015952.SGD","LU2237438978.USD","LU2361045086.USD","LU0289739699.SGD","LU0158827948.USD","LU2089283258.USD","LU1989772923.USD","LU2265009873.SGD"],"gpt_icon":1},{"id":"2483876240","title":"GH Research Reports Third Quarter 2024 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2483876240","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483876240?lang=en_us&edition=fundamental","pubTime":"2024-11-14 20:00","pubTimestamp":1731585600,"startTime":"0","endTime":"0","summary":"Phase 2b clinical trial of GH001 in patients with treatment-resistant depression completed enrolment of the double-blind phase in Q3 2024Phase 1 clinical trial to evaluate proprietary aerosol delivery","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/14/2981003/0/en/GH-Research-Reports-Third-Quarter-2024-Financial-Results-and-Provides-Business-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4196","BK4121","BK4588","BK4535","PPD","BK4561","BK4530","GH","BK4551"],"gpt_icon":0},{"id":"2481904303","title":"Press Release: Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2481904303","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481904303?lang=en_us&edition=fundamental","pubTime":"2024-11-07 21:00","pubTimestamp":1730984400,"startTime":"0","endTime":"0","summary":"SALT LAKE CITY, Nov. 7, 2024 /PRNewswire/ -- Lipocine Inc. , a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced financial results for the third quarter and nine months ended September 30, 2024 and provided a corporate update.-- LPCN 1154, oral brexanolone, is being developed as a treatment for. postpartum depression . It is targeted to be a highly effective,-- The Company has completed labeling studies such as a food effect study. and PK profiling in women with PPD, and is targeting NDA submission for. -- In October, Lipocine announced positive results from a quantitative. administered single doses of LPCN 1154. The results indicated robust. central nervous system  activity of LPCN 1154, with concentration-. and time-dependent post-dose changes in qEEG. The study confirmed GABAA. positive allosteric modulation and supports future development of LPCN. -- In October, Lipocine hosted a virtual","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","BK4232","BK4135","CNS","PPD","LPCN","KOL","UAE","BK4121","GCC","R","BK4007","BK4530","BK4561"],"gpt_icon":0},{"id":"2481702908","title":"Sobi to present new data across its immunology portfolio at the ACR Convergence 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2481702908","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481702908?lang=en_us&edition=fundamental","pubTime":"2024-11-07 19:59","pubTimestamp":1730980740,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., Nov. 07, 2024  -- Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB  , today announced the presentation of four abstracts that highlights data from its immunology portfolio at the ACR Convergence 2024 taking place in Washington, D.C. from November 14–19, 2024.Sobi’s commitment to delivering innovative treatments for people living with immunological diseases is seen in global studies spanning multiple disorders:. Results from two Phase 3 trials evaluating the effect on patient-reported outcomes in patients with chronic refractory gout treated with SEL-212.Initial data on the effect of anti-drug antibodies on serum uric acid  reduction and safety in response to treatment with SEL-212.DISSOLVE 1 Phase 3 study: Results of a post hoc analysis of sustained sUA reduction and safety of SEL-212 in patients with chronic refractory gout living in the United States.Results from a Phase 3 Study and a pooled analysis of two prospective trials evaluating ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/x7YFyGf5t1TpmaBcFH5NNQ--~B/aD0yNzQ7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/c87171b9fa161c1111e7d2f803fd59a9","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/x7YFyGf5t1TpmaBcFH5NNQ--~B/aD0yNzQ7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/c87171b9fa161c1111e7d2f803fd59a9"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sobi-present-data-across-immunology-115900677.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4110","BK4139","LU2413666004.HKD","HSCT","LU1165135440.EUR","SG9999001440.SGD","LU1620156213.USD","BK4530","ACR","PPD","BK4561","MAS","SWOBY","BK4077","BIOVF","BK4121","LU1620156130.USD","BK4086","BK4585","LU1721427968.SGD","LU2413665964.HKD","LU0170899867.USD","LU1543694498.USD","SLE","BK4588","LU1596574779.USD"],"gpt_icon":0},{"id":"2476529592","title":"Sage Therapeutics to Reduce Workforce by 33%, Stock Down","url":"https://stock-news.laohu8.com/highlight/detail?id=2476529592","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476529592?lang=en_us&edition=fundamental","pubTime":"2024-10-19 00:12","pubTimestamp":1729267920,"startTime":"0","endTime":"0","summary":"Sage Therapeutics, Inc. SAGE announced a strategic reorganization and a portfolio reprioritization plan to support its ongoing business operations.As part of this strategic reorganization, SAGE is looking to reduce its current workforce by 33% and implement changes in the leadership team. Shares of the company were down 4.3% in after-hours trading on Thursday, following the announcement of the news.Owing to this reorganization, the company expects to record a non-recurring charge of around $26-$28 million in the fourth quarter of 2024. The restructuring process is likely to extend the company’s cash runway in the near future and support the long-term growth of its business.As part of the reprioritization, SAGE will focus on the commercialization of its depression drug Zurzuvae , which is marketed in partnership with drug giant, Biogen BIIB.Sage Therapeutics will also focus on its neuropsychiatric candidate, dalzanemdor , which is being evaluated in various mid-to-late-stage studies as ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/b7YQi_HTDu1GkQZqPUqgyw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/59b208c03ab625710a229f805a232093","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/b7YQi_HTDu1GkQZqPUqgyw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/59b208c03ab625710a229f805a232093"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sage-therapeutics-reduce-workforce-33-161200239.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","IE00BSNM7G36.USD","VYGR","MCI","LU0820561818.USD","LU0943347566.SGD","BK4139","BK4585","BK4561","BK4504","IE00BWXC8680.SGD","LU2756315664.SGD","LU1551013425.SGD","LU1162221912.USD","LU1914381329.SGD","LU0889565916.HKD","BK4121","LU1778281490.HKD","LU2756315318.SGD","LU0942090050.USD","BK4530","CRL","PPD","BIIB","LU1496350171.SGD","ANIP","IE00B19Z9Z06.USD","IE00B894F039.SGD","LU1496350502.SGD","HD","IE00BZ1G4Q59.USD","IE00B1XK9C88.USD","LU1551013342.USD","LU0689472784.USD","BK4581","LU0079474960.USD","LU1093756168.USD","BK4588","BK4550","PD","LU0234570918.USD","LU0234572021.USD","LU1169589451.USD","LU1169590202.USD","LU1674673428.USD","LU1674673691.USD","SAGE","SG9999001440.SGD","BK4533","BK4532"],"gpt_icon":0},{"id":"2474710893","title":"Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2474710893","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474710893?lang=en_us&edition=fundamental","pubTime":"2024-10-10 20:00","pubTimestamp":1728561600,"startTime":"0","endTime":"0","summary":"Rapid and durable CNS target engagement confirms effective oral delivery of bioidentical brexanolone. Promising results support continued development of oral brexanolone for the treatment of neuropsychiatric disorders. \"We are pleased with the qEEG results that confirm target engagement of oral bioidentical brexanolone, which suggests potential utility in treating numerous psychiatry indications, including depression and anxiety, and neurology indications such as essential tremor and epilepsy,\" said Dr. Mahesh Patel, President and CEO of Lipocine Inc. \"These positive biomarker results and favorable safety profile support further development of oral brexanolone.\". Following a single clinically relevant dose of oral brexanolone, subjects showed mean changes in all oscillatory spectral power bands. As shown in Fig. 1, theta and alpha1 band power were significantly increased in posterior cortical regions, while alpha2 band power decreased. There was considerable beta band amplitude increas","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/vK1pa2w0SX0kMwRctVvAnw--~B/aD0yMTQ7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/4f5425bfaecd2be6a12100ec25a08d49","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/vK1pa2w0SX0kMwRctVvAnw--~B/aD0yMTQ7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/4f5425bfaecd2be6a12100ec25a08d49"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/lipocine-announces-positive-oral-brexanolone-120000142.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lipocine-announces-positive-oral-brexanolone-120000142.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4135","LPCN","BK4530","BK4561","PPD","BK4007","BK4121","CNS"],"gpt_icon":0},{"id":"2474406288","title":"It’s an Impressive Result – Ray Dalio About Duoduo Grocery’s Contribution to PPD Holding Inc (PDD)’s  Annual Profits","url":"https://stock-news.laohu8.com/highlight/detail?id=2474406288","media":"Insider Monkey","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474406288?lang=en_us&edition=fundamental","pubTime":"2024-10-09 03:43","pubTimestamp":1728416635,"startTime":"0","endTime":"0","summary":"We recently compiled a list titled 7 Best Cheap Stocks to Buy According to Billionaire Ray Dalio. In this article, we will look at where PDD Holdings Inc.  ranks among the best cheap stocks to buy according to billionaire Ray Dalio.As of now, Bridgewater Associates is being tagged as a premier asset management firm, which is focused on delivering unique insight and partnership for the most sophisticated global institutional investors. The firm’s investment process revolves around understanding how the world markets and economies work, leveraging cutting-edge technology to validate timeless and universal investment principles.Ray Dalio’s investment principle of “Strategic Selling for Maximum Profit” focuses","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/c3zXb_ESHlhLtvo4DQEsMA--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/39432c8f252ec1ff8c978657224a9958","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/c3zXb_ESHlhLtvo4DQEsMA--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/39432c8f252ec1ff8c978657224a9958"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/impressive-result-ray-dalio-duoduo-194355331.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4535","LU0823038988.USD","LU0329678170.USD","LU0516422440.USD","TQQQ","LU0455707207.USD","LINK","LU0605514214.HKD","LU0516422952.EUR","LU0650527681.SGD","LU0737861772.HKD","BK4561","HK0000320264.USD","LU0329678337.USD","MNQmain","QLD","L","LU0370786039.SGD","IE00B0JY6N72.USD","BK4121","IE00B3M56506.USD","LU0143863784.USD","LU0633140560.USD","NQmain","LU0417516902.SGD","LU0143863198.USD","BK4585","LU0231483743.USD","PSQ","HK0000320223.HKD","BK4553","LU0572944931.SGD","LU0588546209.SGD","BK4501","LU0823039010.USD","PDD","BK4509","LU0633140727.USD","PPD","LU0348805143.USD","LU0359201612.USD","SQQQ","BK4122","BK4558","LU0307460666.USD","QID","BK4530","LU0348825331.USD",".IXIC"],"gpt_icon":1}],"pageSize":16,"totalPage":2,"pageCount":1,"totalSize":22}]}}